Business Context and Reporting Period
This Form 8-K was filed by Imprimis Pharmaceuticals, Inc. on February 13, 2017. The report details a material definitive agreement and the completion of an asset disposition involving the company's Texas-based subsidiary, ImprimisRx TX, Inc. (dba ImprimisRx).
Key Financial Metrics
The filing discloses specific transaction values related to the sale of the subsidiary:
- Cash Consideration Received: $10,000 paid by the buyer, Livernois & London, LLC.
- Liability Assumed by Buyer: $112,578 representing the remaining lease obligation for the Texas facility.
- Revenue, Profit, and Cash Flow: The filing text does not provide clear values for general operating revenue, profit, or cash flow metrics for the reporting period.
- Debt and Liquidity: No general debt or liquidity figures are provided; only the specific lease obligation transfer is noted.
Material Changes
The primary material change is the divestiture of 100% of the issued and outstanding shares of ImprimisRx TX, Inc. The subsidiary had ceased operations in 2016. The transaction does not transfer any intellectual property, products, clients, or existing business operations to the buyer.
Outlook, Risks, and Management Commentary
Management commentary is limited to the description of the Stock Purchase Agreement. The filing notes that the transaction effectively removes the remaining lease obligation of $112,578 from the company's balance sheet. No forward-looking guidance, risk factors, or contingencies beyond the terms of this specific agreement are disclosed in this report.
Key Facts for Investor Verification
- Verify the cessation of operations for ImprimisRx TX, Inc. in 2016 to confirm the asset was non-operating at the time of sale.
- Confirm the total consideration value of $122,578 (cash plus liability relief) relative to the company's overall financial position.
- Review the full text of the Stock Purchase Agreement (Exhibit 10.1) for any undisclosed covenants or future obligations.
- Check subsequent filings to ensure no further liabilities related to the Texas facility remain with Imprimis Pharmaceuticals, Inc.